Usmani, S. Z., Mielnik, M., Alonso, A., Abdallah, A. A., Garg, M., Janowski, W., Koh, Y., Ocio, E. M., Quach, H., Ramasamy, K., Rocafiguera, A. O., Rodriguez-Otero, P., Sandhu, I., Weisel, K. C., Brawley, C., Murillo, M., Pompilus, F., Egger, J. L., Kaisermann, M. C., Hus, M. (2026). DREAMM-9 final analysis: Belantamab mafodotin (belamaf), bortezomib, lenalidomide, and dexamethasone (BVRd) for transplant-ineligible (TI) newly diagnosed multiple myeloma (NDMM).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.7503